Without getting into the weeds, I think Gohibic showed more benefit than lenz in treating late-stage patients. From recall, I think we're looking at improvement of 30% vs 17% in Gohibic vs lenz.
But how will that change when new variants arrive? How could Humanigen improve late-stage efficacy if lenz is combined with their newly-patented anti-viral co-therapy treatment?
It's not a market segment the company wants to pursue. But a very lethal variant could develop at any time, forcing governments to further embrace mAbs.
News 
Market Data 
Discover 
AI
